Roche's com­bo ther­a­py re­duces risk of liv­er can­cer re­turn­ing but rais­es safe­ty ques­tions: #AACR23

OR­LAN­DO — Roche’s Tecen­triq-Avastin com­bi­na­tion, al­ready ap­proved for one in­di­ca­tion, re­duced the risk of can­cer re­cur­rence among pa­tients af­ter they re­ceived surgery for an ear­ly-stage liv­er can­cer.

The Phase III tri­al could change the land­scape of treat­ment for pa­tients in the ear­ly stages of he­pa­to­cel­lu­lar car­ci­no­ma, or HCC, ac­cord­ing to Genen­tech, a unit of Roche. But the re­sults raised po­ten­tial­ly wor­ry­ing safe­ty sig­nals as well, in­clud­ing two pa­tient deaths re­lat­ed to the com­bi­na­tion, though ex­perts said the da­ta were too ear­ly to reach firm con­clu­sions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.